1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth Rate by Type: 2020 VS 2026 1.2.2 Medication 1.2.3 Bone Marrow Transplant 1.2.4 Blood Transfusion 1.2.5 Iron Therapy 1.3 Market by Application 1.3.1 Global Acquired Orphan Blood Diseases Therapeutics Market Share by Application: 2020 VS 2026 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Perspective (2015-2026) 2.2 Global Acquired Orphan Blood Diseases Therapeutics Growth Trends by Regions 2.2.1 Acquired Orphan Blood Diseases Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Acquired Orphan Blood Diseases Therapeutics Historic Market Share by Regions (2015-2020) 2.2.3 Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Market Size 3.1.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Revenue (2015-2020) 3.1.2 Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Players (2015-2020) 3.2 Global Acquired Orphan Blood Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Acquired Orphan Blood Diseases Therapeutics Revenue 3.4 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio 3.4.1 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Acquired Orphan Blood Diseases Therapeutics Revenue in 2019 3.5 Key Players Acquired Orphan Blood Diseases Therapeutics Area Served 3.6 Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service 3.7 Date of Enter into Acquired Orphan Blood Diseases Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Acquired Orphan Blood Diseases Therapeutics Breakdown Data by Type (2015-2026) 4.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Type (2015-2020) 4.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Type (2021-2026) 5 Acquired Orphan Blood Diseases Therapeutics Breakdown Data by Application (2015-2026) 5.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Application (2015-2020) 5.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2026) 6.2 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) 6.3 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) 6.4 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2015-2020) 6.4.1 United States 6.4.2 Canada 7 Europe 7.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2026) 7.2 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) 7.3 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) 7.4 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2015-2020) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 7.4.6 Nordic 7.4.7 Rest of Europe 8 China 8.1 China Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2026) 8.2 China Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) 8.3 China Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) 8.4 China Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2015-2020) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 Southeast Asia 8.4.5 India 8.4.6 Australia 8.4.7 Rest of Asia-Pacific 9 Japan 9.1 Japan Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2026) 9.2 Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) 9.3 Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) 9.4 Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2015-2020) 9.4.1 Mexico 9.4.2 Brazil 10 Southeast Asia 10.1 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size (2015-2026) 10.2 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) 10.3 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) 10.4 Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2015-2020) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 UAE 10.4.4 Rest of Middle East & Africa 11 Key Players Profiles 11.1 Alexion Pharmaceuticals 11.1.1 Alexion Pharmaceuticals Company Details 11.1.2 Alexion Pharmaceuticals Business Overview 11.1.3 Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction 11.1.4 Alexion Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020)) 11.1.5 Alexion Pharmaceuticals Recent Development 11.2 Amgen 11.2.1 Amgen Company Details 11.2.2 Amgen Business Overview 11.2.3 Amgen Acquired Orphan Blood Diseases Therapeutics Introduction 11.2.4 Amgen Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.2.5 Amgen Recent Development 11.3 Celgene Corporation 11.3.1 Celgene Corporation Company Details 11.3.2 Celgene Corporation Business Overview 11.3.3 Celgene Corporation Acquired Orphan Blood Diseases Therapeutics Introduction 11.3.4 Celgene Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.3.5 Celgene Corporation Recent Development 11.4 Eli Lilly 11.4.1 Eli Lilly Company Details 11.4.2 Eli Lilly Business Overview 11.4.3 Eli Lilly Acquired Orphan Blood Diseases Therapeutics Introduction 11.4.4 Eli Lilly Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.4.5 Eli Lilly Recent Development 11.5 Sanofi 11.5.1 Sanofi Company Details 11.5.2 Sanofi Business Overview 11.5.3 Sanofi Acquired Orphan Blood Diseases Therapeutics Introduction 11.5.4 Sanofi Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.5.5 Sanofi Recent Development 11.6 GlaxoSmithKline 11.6.1 GlaxoSmithKline Company Details 11.6.2 GlaxoSmithKline Business Overview 11.6.3 GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Introduction 11.6.4 GlaxoSmithKline Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.6.5 GlaxoSmithKline Recent Development 11.7 Cyclacel Pharmaceuticals 11.7.1 Cyclacel Pharmaceuticals Company Details 11.7.2 Cyclacel Pharmaceuticals Business Overview 11.7.3 Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction 11.7.4 Cyclacel Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.7.5 Cyclacel Pharmaceuticals Recent Development 11.8 Onconova Therapeutics 11.8.1 Onconova Therapeutics Company Details 11.8.2 Onconova Therapeutics Business Overview 11.8.3 Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Introduction 11.8.4 Onconova Therapeutics Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.8.5 Onconova Therapeutics Recent Development 11.9 Incyte Corporation 11.9.1 Incyte Corporation Company Details 11.9.2 Incyte Corporation Business Overview 11.9.3 Incyte Corporation Acquired Orphan Blood Diseases Therapeutics Introduction 11.9.4 Incyte Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.9.5 Incyte Corporation Recent Development 11.10 CTI BioPharma 11.10.1 CTI BioPharma Company Details 11.10.2 CTI BioPharma Business Overview 11.10.3 CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Introduction 11.10.4 CTI BioPharma Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) 11.10.5 CTI BioPharma Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 3. Key Players of Medication Table 4. Key Players of Bone Marrow Transplant Table 5. Key Players of Blood Transfusion Table 6. Key Players of Iron Therapy Table 7. Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 8. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026 Table 9. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Regions (2015-2020) (US$ Million) Table 10. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2015-2020) Table 11. Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 12. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2021-2026) Table 13. Acquired Orphan Blood Diseases Therapeutics Market Market Trends Table 14. Acquired Orphan Blood Diseases Therapeutics Market Drivers Table 15. Acquired Orphan Blood Diseases Therapeutics Market Challenges Table 16. Acquired Orphan Blood Diseases Therapeutics Market Restraints Table 17. Global Acquired Orphan Blood Diseases Therapeutics Revenue by Players (2015-2020) (US$ Million) Table 18. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Players (2015-2020) Table 19. Global Top Acquired Orphan Blood Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acquired Orphan Blood Diseases Therapeutics as of 2019) Table 20. Global Acquired Orphan Blood Diseases Therapeutics by Players Market Concentration Ratio (CR5 and HHI) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million) Table 25. Global Acquired Orphan Blood Diseases Therapeutics Market Size Share by Type (2015-2020) Table 26. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Type (2021-2026) Table 27. Global Acquired Orphan Blood Diseases Therapeutics Market Size Share by Application (2015-2020) Table 28. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million) Table 29. Global Acquired Orphan Blood Diseases Therapeutics Market Size Share by Application (2021-2026) Table 30. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million) Table 31. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020) Table 32. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million) Table 33. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020) Table 34. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020) Table 35. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2015-2020) Table 36. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million) Table 37. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020) Table 38. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million) Table 39. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020) Table 40. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020) Table 41. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2015-2020) Table 42. China Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million) Table 43. China Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020) Table 44. China Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million) Table 45. China Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020) Table 46. China Acquired Orphan Blood Diseases Therapeutics Market Size by Region (US$ Million) (2015-2020) Table 47. China Acquired Orphan Blood Diseases Therapeutics Market Share by Region (2015-2020) Table 48. Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million) Table 49. Japan Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020) Table 50. Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million) Table 51. Japan Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020) Table 52. Japan Acquired Orphan Blood Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020) Table 53. Japan Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2015-2020) Table 54. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2015-2020) (US$ Million) Table 55. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2015-2020) Table 56. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2015-2020) (US$ Million) Table 57. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2015-2020) Table 58. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size by Country (US$ Million) (2015-2020) Table 59. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2015-2020) Table 60. Alexion Pharmaceuticals Company Details Table 61. Alexion Pharmaceuticals Business Overview Table 62. Alexion Pharmaceuticals Product Table 63. Alexion Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 64. Alexion Pharmaceuticals Recent Development Table 65. Amgen Company Details Table 66. Amgen Business Overview Table 67. Amgen Product Table 68. Amgen Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 69. Amgen Recent Development Table 70. Celgene Corporation Company Details Table 71. Celgene Corporation Business Overview Table 72. Celgene Corporation Product Table 73. Celgene Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 74. Celgene Corporation Recent Development Table 75. Eli Lilly Company Details Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Product Table 78. Eli Lilly Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 79. Eli Lilly Recent Development Table 80. Sanofi Company Details Table 81. Sanofi Business Overview Table 82. Sanofi Product Table 83. Sanofi Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 84. Sanofi Recent Development Table 85. GlaxoSmithKline Company Details Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Product Table 88. GlaxoSmithKline Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 89. GlaxoSmithKline Recent Development Table 90. Cyclacel Pharmaceuticals Company Details Table 91. Cyclacel Pharmaceuticals Business Overview Table 92. Cyclacel Pharmaceuticals Product Table 93. Cyclacel Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 94. Cyclacel Pharmaceuticals Recent Development Table 95. Onconova Therapeutics Business Overview Table 96. Onconova Therapeutics Product Table 97. Onconova Therapeutics Company Details Table 98. Onconova Therapeutics Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 99. Onconova Therapeutics Recent Development Table 100. Incyte Corporation Company Details Table 101. Incyte Corporation Business Overview Table 102. Incyte Corporation Product Table 103. Incyte Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 104. Incyte Corporation Recent Development Table 105. CTI BioPharma Company Details Table 106. CTI BioPharma Business Overview Table 107. CTI BioPharma Product Table 108. CTI BioPharma Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) (US$ Million) Table 109. CTI BioPharma Recent Development Table 110. Research Programs/Design for This Report Table 111. Key Data Information from Secondary Sources Table 112. Key Data Information from Primary Sources List of Figures Figure 1. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Type: 2020 VS 2026 Figure 2. Medication Features Figure 3. Bone Marrow Transplant Features Figure 4. Blood Transfusion Features Figure 5. Iron Therapy Features Figure 6. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Application: 2020 VS 2026 Figure 7. Hospitals Case Studies Figure 8. Clinics Case Studies Figure 9. Others Case Studies Figure 10. Acquired Orphan Blood Diseases Therapeutics Report Years Considered Figure 11. Global Acquired Orphan Blood Diseases Therapeutics Market Size (US$ Million), YoY Growth 2015-2026 Figure 12. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions: 2020 VS 2026 Figure 13. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2021-2026) Figure 14. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Players in 2019 Figure 15. Global Top Acquired Orphan Blood Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acquired Orphan Blood Diseases Therapeutics as of 2019 Figure 16. The Top 10 and 5 Players Market Share by Acquired Orphan Blood Diseases Therapeutics Revenue in 2019 Figure 17. North America Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 18. United States Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 19. Canada Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 20. Europe Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 21. Germany Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 22. France Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 23. U.K. Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 24. Italy Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 25. Russia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 26. Nordic Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 27. Rest of Europe Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 28. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 29. China Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 30. Japan Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 31. South Korea Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 32. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 33. India Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 34. Australia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 35. Rest of Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 36. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 37. Mexico Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 38. Brazil Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 39. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 40. Turkey Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 41. Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 42. UAE Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 43. Rest of Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million) Figure 44. Alexion Pharmaceuticals Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 45. Amgen Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 46. Celgene Corporation Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 47. Eli Lilly Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 48. Sanofi Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 49. GlaxoSmithKline Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 50. Cyclacel Pharmaceuticals Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 51. Onconova Therapeutics Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 52. Incyte Corporation Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 53. CTI BioPharma Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2015-2020) Figure 54. Bottom-up and Top-down Approaches for This Report Figure 55. Data Triangulation Figure 56. Key Executives Interviewed

Alexion Pharmaceuticals Amgen Celgene Corporation Eli Lilly Sanofi GlaxoSmithKline Cyclacel Pharmaceuticals Onconova Therapeutics Incyte Corporation CTI BioPharma